INDSWFTLABNSEInd-Swift Laboratories Limited· PharmaceuticalsMinimalNeutral
Announced Tue, 19 May · 16:16 IST

NAVRATTAN MUNJAL has Submitted to the Exchange a copy of Disclosure under Regulation 31(4) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011

INDSWFTLAB · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close
+0.8%1-day move
₹134.00
prior close
₹134.10
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
-0.7+0.4+0.6+2.5+0.8-1.5-1.0+2.2+0.7+23.1+18.5+40.7+74.8
Up moveDown movePending
AI summary

Navrattan Munjal, acting on behalf of all promoters and the promoter group of Ind-Swift Laboratories Limited, has submitted a confirmation to BSE and NSE under SEBI Regulation 31(4). The filing certifies that no new share encumbrances (pledges or charges) were created by the promoters and persons acting in concert (PAC) during the financial year ended 31 March 2026, beyond what has already been disclosed to the exchanges. The filing lists 20 entities belonging to the promoter group including Essix Biosciences Limited, various Munjal and Mehta family members, and individuals. The company trades on BSE (scrip code 532305) and NSE (symbol INDSWFTLAB).

Likely market impact

A 'no new encumbrance' disclosure is a positive signal as it indicates promoters have not leveraged their shareholding through fresh pledges, reducing risk of forced selling. Shareholders can view this as a sign of financial stability within the promoter group.